Citations for
1AKT1S1, CHEK2
CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer.
Zhao W, Chen S, Hou X, Chen G, Zhao Y.
Cell Physiol Biochem. 45(4):1590-1602. doi: 10.1159/000487724. Epub 2018 Feb 21 2018
2BRCA1, CEP72, CHEK2
The putative oncogene CEP72 inhibits the mitotic function of BRCA1 and induces chromosomal instability.
Lüddecke S, Ertych N, Stenzinger A, Weichert W, Beissbarth T, Dyczkowski J, Gaedcke J, Valerius O, Braus GH, Kschischo M, Bastians H.
Oncogene 35(18):2398-406. doi: 10.1038/onc.2015.290. 2016
3CHEK2, LFS2
Case report of a Li-Fraumeni syndrome-like phenotype with a de novo mutation in CHEK2.
Zhuang X, Li Y, Cao H, Wang T, Chen J, Liu J, Lin L, Ye R, Li X, Liu S, Li W, Lv Y, Zhang J, He C, Xu X, Wang Z, Huang C, Liu X, Wang L.
Medicine (Baltimore) 95(29):e4251. doi: 10.1097/MD.0000000000004251. 2016
4AURKA, BRCA1, CHEK2
CHK2-BRCA1 tumor-suppressor axis restrains oncogenic Aurora-A kinase to ensure proper mitotic microtubule assembly.
Ertych N, Stolz A, Valerius O, Braus GH, Bastians H.
Proc Natl Acad Sci U S A 113(7):1817-22. doi: 10.1073/pnas.1525129113. Epub 2016 Feb 1. 2016
5ATM, CHEK2
Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.
Chou WC, Hu LY, Hsiung CN, Shen CY.
Carcinogenesis 36(8):832-40. doi: 10.1093/carcin/bgv079. Epub 2015 May 29. 2015
6CHEK1, CHEK2
Checkpoint kinase 2 is required for efficient immunoglobulin diversification.
Davari K, Frankenberger S, Schmidt A, Tomi NS, Jungnickel B.
Cell Cycle 13(23):3659-69. doi: 10.4161/15384101.2014.964112. 2014
7CHEK2
CHK2 kinase in the DNA damage response and beyond.
Zannini L, Delia D, Buscemi G.
J Mol Cell Biol 6(6):442-57. doi: 10.1093/jmcb/mju045. Epub 2014 Nov 17. Review. 2014
8CCAR2, CHEK2, SIRT1
Chk2 and REGγ-dependent DBC1 regulation in DNA damage induced apoptosis.
Magni M, Ruscica V, Buscemi G, Kim JE, Nachimuthu BT, Fontanella E, Delia D, Zannini L.
Nucleic Acids Res 42(21):13150-60. doi: 10.1093/nar/gku1065. Epub 2014 Oct 31. 2014
9CHEK2
In vivo role of checkpoint kinase 2 in signaling telomere dysfunction.
García-Beccaria M, Martínez P, Flores JM, Blasco MA.
Aging Cell 13(5):810-6. doi: 10.1111/acel.12237. Epub 2014 Jun 12. 2014
10AURKB, CHEK2, TTK
Chk2 prevents mitotic exit when the majority of kinetochores are unattached.
Petsalaki E, Zachos G.
J Cell Biol 205(3):339-56. doi: 10.1083/jcb.201310071. Epub 2014 May 5. 2014
11CHEK2, TTK
Phosphorylation at threonine 288 by cell cycle checkpoint kinase 2 (CHK2) controls human monopolar spindle 1 (Mps1) kinetochore localization.
Yeh CW, Yu ZC, Chen PH, Cheng YC, Shieh SY.
J Biol Chem 289(22):15319-27. doi: 10.1074/jbc.M114.552273. Epub 2014 Apr 24. 2014
12CHEK2
Chk2 regulates cell cycle progression during mouse oocyte maturation and early embryo development.
Dai XX, Duan X, Liu HL, Cui XS, Kim NH, Sun SC.
Mol Cells 37(2):126-32. doi: 10.14348/molcells.2014.2259. Epub 2014 Feb 19. 2014
13CHEK2
Reversal of female infertility by Chk2 ablation reveals the oocyte DNA damage checkpoint pathway.
Bolcun-Filas E, Rinaldi VD, White ME, Schimenti JC.
Science 343(6170):533-6. doi: 10.1126/science.1247671. 2014
14CDK11A, CHEK2
CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110).
Choi HH, Choi HK, Jung SY, Hyle J, Kim BJ, Yoon K, Cho EJ, Youn HD, Lahti JM, Qin J, Kim ST.
Oncogene 33(1):108-15. doi: 10.1038/onc.2012.535. Epub 2012 Nov 26. 2014
15CHEK2, RAD9A, SLX4
DNA-repair scaffolds dampen checkpoint signalling by counteracting the adaptor Rad9.
Ohouo PY, Bastos de Oliveira FM, Liu Y, Ma CJ, Smolka MB.
Nature 493(7430):120-4. doi: 10.1038/nature11658. Epub 2012 Nov 18. 2013
16CHEK2, NCOR2, PPM1D
The co-repressor SMRT delays DNA damage-induced caspase activation by repressing pro-apoptotic genes and modulating the dynamics of checkpoint kinase 2 activation.
Scafoglio C, Smolka M, Zhou H, Perissi V, Rosenfeld MG.
PLoS One 8(5):e59986. doi: 10.1371/journal.pone.0059986. Print 2013. 2013
17CHEK2, RCHY1
The E3 ligase PIRH2 polyubiquitylates CHK2 and regulates its turnover.
Bohgaki M, Hakem A, Halaby MJ, Bohgaki T, Li Q, Bissey PA, Shloush J, Kislinger T, Sanchez O, Sheng Y, Hakem R.
Cell Death Differ 20(6):812-22. doi: 10.1038/cdd.2013.7. Epub 2013 Mar 1. 2013
18CHEK2
Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
Roeb W, Higgins J, King MC.
Hum Mol Genet 21(12):2738-44. doi: 10.1093/hmg/dds101. Epub 2012 Mar 13. 2012
19CHEK2
Chk2 mediates RITA-induced apoptosis.
de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG.
Cell Death Differ 19(6):980-9. doi: 10.1038/cdd.2011.182. Epub 2011 Dec 9. 2012
20CHEK2, MUS81
Inactivation of chk2 and mus81 leads to impaired lymphocytes development, reduced genomic instability, and suppression of cancer.
El Ghamrasni S, Pamidi A, Halaby MJ, Bohgaki M, Cardoso R, Li L, Venkatesan S, Sethu S, Hirao A, Mak TW, Hande MP, Hakem A, Hakem R.
PLoS Genet 7(5):e1001385. Epub 2011 May 19. 2011
21BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MRE11A, MSH6, NBN, PALB2, RAD50, RAD51c, TP53
Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, Roeb W, Agnew KJ, Stray SM, Wickramanayake A, Norquist B, Pennington KP, Garcia RL, King MC, Swisher EM.
Proc Natl Acad Sci U S A 108(44):18032-7. doi: 10.1073/pnas.1115052108. Epub 2011 Oct 17. 2011
22ABL1, CHEK2, EWSR1, MAP4K2
The Ewing sarcoma protein regulates DNA damage-induced alternative splicing.
Paronetto MP, Miñana B, Valcárcel J.
Mol Cell 43(3):353-68. doi: 10.1016/j.molcel.2011.05.035. 2011
23CHEK2, PER3
Per3, a circadian gene, is required for Chk2 activation in human cells.
Im JS, Jung BH, Kim SE, Lee KH, Lee JK.
FEBS Lett 584(23):4731-4. Epub 2010 Nov 9. 2010
24CHEK1, CHEK2
Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo.
Niida H, Murata K, Shimada M, Ogawa K, Ohta K, Suzuki K, Fujigaki H, Khaw AK, Banerjee B, Hande MP, Miyamoto T, Miyoshi I, Shirai T, Motoyama N, Delhase M, Appella E, Nakanishi M.
EMBO J 29(20):3558-70. Epub 2010 Sep 10. 2010
25CHEK2
Interdependent phosphorylation within the kinase domain T-loop Regulates CHK2 activity.
Guo X, Ward MD, Tiedebohl JB, Oden YM, Nyalwidhe JO, Semmes OJ.
J Biol Chem 285(43):33348-57. Epub 2010 Aug 16. 2010
26CHEK2
A protein phosphatase feedback mechanism regulates the basal phosphorylation of Chk2 kinase in the absence of DNA damage.
Carlessi L, Buscemi G, Fontanella E, Delia D.
Biochim Biophys Acta 1803(10):1213-23. Epub 2010 Jun 22. 2010
27CHEK2
Centrosomal Chk2 in DNA damage responses and cell cycle progression.
Golan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF.
Cell Cycle 9(13):2647-56. 2010
28CHEK2
CHK2-independent induction of telomere dysfunction checkpoints in stem and progenitor cells.
Nalapareddy K, Choudhury AR, Gompf A, Ju Z, Ravipati S, Leucht T, Lechel A, Rudolph KL.
EMBO Rep 11(8):619-25. Epub 2010 Jun 25. 2010
29CHEK2
A mitotic role for the DNA damage-responsive CHK2 kinase.
Sato K, Ohta T, Venkitaraman AR.
Nat Cell Biol 12(5):424-5. No abstract available. 2010
30CHEK2
Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity.
Berge EO, Staalesen V, Straume AH, Lillehaug JR, Lønning PE.
Biochim Biophys Acta 1803(3):386-95. Epub 2010 Jan 15. 2010
31CHEK2
Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase.
Cai Z, Chehab NH, Pavletich NP.
Mol Cell 35(6):818-29. 2009
32CHEK2
Chk2 protects against radiation-induced genomic instability.
MacLaren A, Slavin D, McGowan CH.
Radiat Res 172(4):463-72. 2009
33ATML, CHEK2, STRAP, TTC5
ATM and Chk2 kinase target the p53 cofactor Strap.
Adams CJ, Graham AL, Jansson M, Coutts AS, Edelmann M, Smith L, Kessler B, La Thangue NB.
EMBO Rep 9(12):1222-9. Epub 2008 Oct 3. 2008
34CHEK2
Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
Cybulski C, Wokolorczyk D, Kladny J, Kurzwaski G, Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Gorski B, D Ecedil Bniak T, Narod SA, Lubinski J.
Eur J Hum Genet 15(2):237-41. Epub 2006 Nov 15. 2007
35CHEK2
Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case control study.
Brennan P, McKay J, Moore L, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Chow WH, Rothman N, Chabrier A, Gaborieau V, Odefrey F, Southey M, Hashibe M, Hall J, Boffetta P, Peto J, Peto R, Hung RJ.
Hum Mol Genet 16(15):1794-801. Epub 2007 May 21. 2007
36CHEK2
Inherited association of breast and colorectal cancer: limited role of CHEK2 compared with high-penetrance genes.
Naseem H, Boylan J, Speake D, Leask K, Shenton A, Lalloo F, Hill J, Trump D, Evans DG.
Clin Genet 70(5):388-95. 2006
37CHEK2
A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer.
Cybulski C, Wokolorczyk D, Huzarski T, Byrski T, Gronwald J, Gorski B, Debniak T, Masojc B, Jakubowska A, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Zdrojowy R, Malkiewicz B, Borkowski A, Borkowski T, Szwiec M, Narod SA, Lubinski J.
J Med Genet 43(11):863-6. 2006
38CHEK2, PPP2R2A
Fusion of the tumor-suppressor gene CHEK2 and the gene for the regulatory subunit B of protein phosphatase 2 PPP2R2A in childhood teratoma.
Jin Y, Mertens F, Kullendorff CM, Panagopoulos I.
Neoplasia 8(5):413-8. 2006
39CHEK2
CHEK2 is a multiorgan cancer susceptibility gene.
Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, Zlowocka E, Lenner M, Grabowska E, Nej K, Castaneda J, Medrek K, Szymanska A, Szymanska J, Kurzawski G, Suchy J, Oszurek O, Witek A, Narod SA, Lubinski J.
Am J Hum Genet 75(6):1131-5. Epub 2004 Oct 18. 2004
40CHEK2
Mutations in CHEK2 associated with prostate cancer risk
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC, Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W.
Am J Hum Genet 72(2):270-80. 2003
41CHEK2
Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility.
Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, van den Ouweland A, Futreal PA, Nathanson KL, Weber BL, Easton DF, Stratton MR, Rahman N; Breast Cancer Linkage Consortium.
Am J Hum Genet 72(4):1023-8. Epub 2003 Feb 27. 2003
42CHEK2
The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype.
Meijers-Heijboer H, Wijnen J, Vasen H, Wasielewski M, Wagner A, Hollestelle A, Elstrodt F, van den Bos R, de Snoo A, Fat GT, Brekelmans C, Jagmohan S, Franken P, Verkuijlen P, van den Ouweland A, Chapman P, Tops C, Moslein G, Burn J, Lynch H, Klijn J, Fodde R, Schutte M.
Am J Hum Genet 72(5):1308-14. Epub 2003 Apr 10. 2003
43ATM, CHEK2, TP53
Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage.
Keramaris E, Hirao A, Slack RS, Mak TW, Park DS.
J Biol Chem 278(39):37782-9. Epub 2003 Jul 11. 2003
44CHEK2
Identification of potential binding sites for the FHA domain of human Chk2 by in vitro binding studies.
Qin D, Lee H, Yuan C, Ju Y, Tsai MD.
Biochem Biophys Res Commun 311(4):803-8. 2003
45CHEK2
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors.
Miller CW, Ikezoe T, Krug U, Hofmann WK, Tavor S, Vegesna V, Tsukasaki K, Takeuchi S, Koeffler HP.
Genes Chromosomes Cancer 33(1):17-21. 2002
46CHEK2
A robust method for detecting CHK2/RAD53 mutations in genomic DNA.
Sodha N, Houlston RS, Williams R, Yuille MA, Mangion J, Eeles RA.
Hum Mutat 19(2):173-7. 2002
47CHEK2
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR.
Nat Genet 31(1):55-9. 2002
48CHEK2
A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.
Vahteristo P, Bartkova J, Eerola H, Syrjakoski K, Ojala S, Kilpivaara O, Tamminen A, Kononen J, Aittomaki K, Heikkila P, Holli K, Blomqvist C, Bartek J, Kallioniemi OP, Nevanlinna H.
Am J Hum Genet 71(2):432-8. 2002
49CHEK2, PLK3, TP53
Mammalian Polo-like kinase 3 (Plk3) is a multifunctional protein involved in stress response pathways.
Bahassi el M, Conn CW, Myer DL, Hennigan RF, McGowan CH, Sanchez Y, Stambrook PJ.
Oncogene 21(43):6633-40. 2002
50CHEK2
CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas.
Tort F, Hernandez S, Bea S, Martinez A, Esteller M, Herman JG, Puig X, Camacho E, Sanchez M, Nayach I, Lopez-Guillermo A, Fernandez PL, Colomer D, Hernandez L, Campo E.
Blood 100(13):4602-8. Epub 2002 Aug 01. 2002
51ATM, CDC25A, CHEK2
The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis.
Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J.
Nature 410(6830):842-7. 2001
52CHEK2, LFS2
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni Syndrome.
Lee SB, Kim SH, Bell DW, Wahrer DC, Schiripo TA, Jorczak MM, Sgroi DC, Garber JE, Li FP, Nichols KE, Varley JM, Godwin AK, Shannon KM, Harlow E, Haber DA.
Cancer Res 61(22):8062-7. 2001
53TP53, CHEK2, LFS1, LFS2
p53, CHK2, and CHK1 genes in Finnish families with Li-Fraumeni syndrome: further evidence of CHK2 in inherited cancer predisposition.
Vahteristo P, Tamminen A, Karvinen P, Eerola H, Eklund C, Aaltonen LA, Blomqvist C, Aittomaki K, Nevanlinna H.
Cancer Res 61(15):5718-22. 2001
54CHEK2
Mutation analysis of the CHK2 gene in families with hereditary breast cancer.
Allinen M, Huusko P, Mantyniemi S, Launonen V, Winqvist R.
Br J Cancer 85(2):209-12. 2001
55CHEK2
DNA damage-induced activation of p53 by the checkpoint kinase Chk2.
Hirao A, Kong YY, Matsuoka S, Wakeham A, Ruland J, Yoshida H, Liu D, Elledge SJ, Mak TW.
Science 287(5459):1824-7. 2000
56CHEK2
Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway.
Chaturvedi P, Eng WK, Zhu Y, Mattern MR, Mishra R, Hurle MR, Zhang X, Annan RS, Lu Q, Faucette LF, Scott GF, Li X, Carr SA, Johnson RK, Winkler JD, Zhou BB.
Oncogene 18(28):4047-54 1999
57CHEK2
A human Cds1-related kinase that functions downstream of ATM protein in the cellular response to DNA damage.
Brown AL, Lee CH, Schwarz JK, Mitiku N, Piwnica-Worms H, Chung JH.
Proc Natl Acad Sci U S A 96(7):3745-50 1999
58CHEK2
A human homologue of the checkpoint kinase Cds1 directly inhibits Cdc25 phosphatase.
Blasina A, de Weyer IV, Laus MC, Luyten WH, Parker AE, McGowan CH.
Curr Biol 9(1):1-10 1999
59LFS2, CHEK2
Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome.
Bell DW, Varley JM, Szydlo TE, Kang DH, Wahrer DC, Shannon KE, Lubratovich M, Verselis SJ, Isselbacher KJ, Fraumeni JF, Birch JM, Li FP, Garber JE, Haber DA.
Science 286(5449):2528-31 1999
60CHEK2
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase.
Matsuoka S, Huang M, Elledge SJ.
Science 282(5395):1893-7 1998